583 related articles for article (PubMed ID: 11922748)
21. Formation of indigo by recombinant mammalian cytochrome P450.
Gillam EM; Aguinaldo AM; Notley LM; Kim D; Mundkowski RG; Volkov AA; Arnold FH; Soucek P; DeVoss JJ; Guengerich FP
Biochem Biophys Res Commun; 1999 Nov; 265(2):469-72. PubMed ID: 10558891
[TBL] [Abstract][Full Text] [Related]
22. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs.
Shimada T; Yamazaki H; Mimura M; Wakamiya N; Ueng YF; Guengerich FP; Inui Y
Drug Metab Dispos; 1996 May; 24(5):515-22. PubMed ID: 8723730
[TBL] [Abstract][Full Text] [Related]
23. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans.
Kurian JR; Bajad SU; Miller JL; Chin NA; Trepanier LA
J Pharmacol Exp Ther; 2004 Dec; 311(3):1171-8. PubMed ID: 15302896
[TBL] [Abstract][Full Text] [Related]
24. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride.
Huskey SW; Dean DC; Miller RR; Rasmusson GH; Chiu SH
Drug Metab Dispos; 1995 Oct; 23(10):1126-35. PubMed ID: 8654202
[TBL] [Abstract][Full Text] [Related]
25. Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes.
Chen H; Howald WN; Juchau MR
Drug Metab Dispos; 2000 Mar; 28(3):315-22. PubMed ID: 10681376
[TBL] [Abstract][Full Text] [Related]
26. Influence of glutathione on the catalytic activity of reconstituted cytochrome P450 3A4.
Kim BR; Kim DH
Biochem Biophys Res Commun; 1998 Jan; 242(1):209-12. PubMed ID: 9439637
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
Dong MS; Yamazaki H; Guo Z; Guengerich FP
Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
[TBL] [Abstract][Full Text] [Related]
28. The kinetic and spectral characterization of the E. coli-expressed mammalian CYP4A7: cytochrome b5 effects vary with substrate.
Loughran PA; Roman LJ; Miller RT; Masters BS
Arch Biochem Biophys; 2001 Jan; 385(2):311-21. PubMed ID: 11368012
[TBL] [Abstract][Full Text] [Related]
29. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes.
Ghosal A; Hapangama N; Yuan Y; Lu X; Horne D; Patrick JE; Zbaida S
Biopharm Drug Dispos; 2003 Dec; 24(9):375-84. PubMed ID: 14689466
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of the reduction of cytochrome b5 with mutations in its membrane-binding domain.
Wu FF; Vergères G; Waskell L
Arch Biochem Biophys; 1994 Feb; 308(2):380-6. PubMed ID: 7906503
[TBL] [Abstract][Full Text] [Related]
31. Biochemical characterization of lauric acid omega-hydroxylation by a CYP4A1/NADPH-cytochrome P450 reductase fusion protein.
Chaurasia CS; Alterman MA; Lu P; Hanzlik RP
Arch Biochem Biophys; 1995 Feb; 317(1):161-9. PubMed ID: 7872779
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine.
Caro AA; Cederbaum AI
Biochem Pharmacol; 2005 Apr; 69(7):1081-93. PubMed ID: 15763544
[TBL] [Abstract][Full Text] [Related]
35. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1.
Shimada T; Gillam EM; Sutter TR; Strickland PT; Guengerich FP; Yamazaki H
Drug Metab Dispos; 1997 May; 25(5):617-22. PubMed ID: 9152602
[TBL] [Abstract][Full Text] [Related]
36. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4.
Komatsu T; Yamazaki H; Asahi S; Gillam EM; Guengerich FP; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Nov; 28(11):1361-8. PubMed ID: 11038165
[TBL] [Abstract][Full Text] [Related]
37. Expression, purification, and physical properties of recombinant flavocytochrome fusion proteins containing rat cytochrome b(5) linked to NADPH-cytochrome P450 reductase by different membrane-binding segments.
Gilep AA; Guryev OL; Usanov SA; Estabrook RW
Arch Biochem Biophys; 2001 Jun; 390(2):222-34. PubMed ID: 11396925
[TBL] [Abstract][Full Text] [Related]
38. The effects of cytochrome b5, NADPH-P450 reductase, and lipid on the rate of 6 beta-hydroxylation of testosterone as catalyzed by a human P450 3A4 fusion protein.
Shet MS; Faulkner KM; Holmans PL; Fisher CW; Estabrook RW
Arch Biochem Biophys; 1995 Apr; 318(2):314-21. PubMed ID: 7733659
[TBL] [Abstract][Full Text] [Related]
39. Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 1B1 variants in Escherichia coli.
Shimada T; Tsumura F; Gillam EM; Guengerich FP; Inoue K
Protein Expr Purif; 2000 Oct; 20(1):73-80. PubMed ID: 11035953
[TBL] [Abstract][Full Text] [Related]
40. Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Ueng YF; Kuwabara T; Chun YJ; Guengerich FP
Biochemistry; 1997 Jan; 36(2):370-81. PubMed ID: 9003190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
